Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT.
ABSTINENCE
ACCELEROMETER
ADULT
BEHAVIOUR CHANGE
COST-BENEFIT ANALYSIS
EXERCISE
GOAL-SETTING
MEDIATION
MOTIVATIONAL INTERVIEWING
MOTIVATIONAL SUPPORT
PHYSICAL ACTIVITY
PRIMARY HEALTH CARE
PROCESS EVALUATION
QUALITATIVE
QUALITY OF LIFE
QUALITY-ADJUSTED LIFE-YEARS
QUITTING
RCT
REDUCTION
SELF-DETERMINATION THEORY
SELF-MONITORING
SMOKING
Journal
Health technology assessment (Winchester, England)
ISSN: 2046-4924
Titre abrégé: Health Technol Assess
Pays: England
ID NLM: 9706284
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
medline:
10
4
2023
entrez:
6
4
2023
pubmed:
7
4
2023
Statut:
ppublish
Résumé
Physical activity can support smoking cessation for smokers wanting to quit, but there have been no studies on supporting smokers wanting only to reduce. More broadly, the effect of motivational support for such smokers is unclear. The objectives were to determine if motivational support to increase physical activity and reduce smoking for smokers not wanting to immediately quit helps reduce smoking and increase abstinence and physical activity, and to determine if this intervention is cost-effective. This was a multicentred, two-arm, parallel-group, randomised (1 : 1) controlled superiority trial with accompanying trial-based and model-based economic evaluations, and a process evaluation. Participants from health and other community settings in four English cities received either the intervention ( The intervention consisted of up to eight face-to-face or telephone behavioural support sessions to reduce smoking and increase physical activity. The main outcome measures were carbon monoxide-verified 6- and 12-month floating prolonged abstinence (primary outcome), self-reported number of cigarettes smoked per day, number of quit attempts and carbon monoxide-verified abstinence at 3 and 9 months. Furthermore, self-reported (3 and 9 months) and accelerometer-recorded (3 months) physical activity data were gathered. Process items, intervention costs and cost-effectiveness were also assessed. The average age of the sample was 49.8 years, and participants were predominantly from areas with socioeconomic deprivation and were moderately heavy smokers. The intervention was delivered with good fidelity. Few participants achieved carbon monoxide-verified 6-month prolonged abstinence [nine (2.0%) in the intervention group and four (0.9%) in the control group; adjusted odds ratio 2.30 (95% confidence interval 0.70 to 7.56)] or 12-month prolonged abstinence [six (1.3%) in the intervention group and one (0.2%) in the control group; adjusted odds ratio 6.33 (95% confidence interval 0.76 to 53.10)]. At 3 months, the intervention participants smoked fewer cigarettes than the control participants (21.1 vs. 26.8 per day). Intervention participants were more likely to reduce cigarettes by ≥ 50% by 3 months [18.9% vs. 10.5%; adjusted odds ratio 1.98 (95% confidence interval 1.35 to 2.90] and 9 months [14.4% vs. 10.0%; adjusted odds ratio 1.52 (95% confidence interval 1.01 to 2.29)], and reported more moderate-to-vigorous physical activity at 3 months [adjusted weekly mean difference of 81.61 minutes (95% confidence interval 28.75 to 134.47 minutes)], but not at 9 months. Increased physical activity did not mediate intervention effects on smoking. The intervention positively influenced most smoking and physical activity beliefs, with some intervention effects mediating changes in smoking and physical activity outcomes. The average intervention cost was estimated to be £239.18 per person, with an overall additional cost of £173.50 (95% confidence interval -£353.82 to £513.77) when considering intervention and health-care costs. The 1.1% absolute between-group difference in carbon monoxide-verified 6-month prolonged abstinence provided a small gain in lifetime quality-adjusted life-years (0.006), and a minimal saving in lifetime health-care costs (net saving £236). There was no evidence that behavioural support for smoking reduction and increased physical activity led to meaningful increases in prolonged abstinence among smokers with no immediate plans to quit smoking. The intervention is not cost-effective. Prolonged abstinence rates were much lower than expected, meaning that the trial was underpowered to provide confidence that the intervention doubled prolonged abstinence. Further research should explore the effects of the present intervention to support smokers who want to reduce prior to quitting, and/or extend the support available for prolonged reduction and abstinence. This trial is registered as ISRCTN47776579. This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in NHS pharmacological and behavioural support helps smokers wanting to quit, and physical activity may also help. It is unclear if behavioural support for those not ready to quit may lead to more quit attempts and abstinence from smoking. A total of 915 smokers who wanted to reduce their smoking, but who had not yet quit, were recruited and randomised to receive an intervention or brief support as usual (brief advice to quit), in Plymouth, London, Oxford and Nottingham. The intervention involved up to eight sessions (by telephone or in person) of motivational support to reduce smoking and increase physical activity (and more sessions to support a quit attempt). Participants self-reported smoking and physical activity information at the start of the trial and after 3 and 9 months. Self-reported quitters confirmed their abstinence with a biochemical test of expired air or saliva. Our main interest was in whether or not the groups differed in the proportion who remained abstinent for at least 6 months. Overall, only 1–2% remained abstinent for 6 months. Although it appeared that a greater proportion did so after receiving the intervention, because few participants were abstinent, the results are not conclusive. However, the intervention had beneficial effects on less rigorous outcomes, including a reduction in the self-reported number of cigarettes smoked, and a greater proportion of intervention than control participants with self-reported and biochemically verified abstinence at 3 months. The intervention also helped participants to reduce, by at least half, the number of cigarettes they smoked at 3 and 9 months, and to report more physical activity, but only at 3 months. Despite reasonable intervention engagement and some short-term changes in smoking and physical activity, the trial does not provide evidence that this intervention would help smokers to quit for at least 6 months nor would it be cost-effective, with an average cost of £239 per smoker.
Sections du résumé
Background
Physical activity can support smoking cessation for smokers wanting to quit, but there have been no studies on supporting smokers wanting only to reduce. More broadly, the effect of motivational support for such smokers is unclear.
Objectives
The objectives were to determine if motivational support to increase physical activity and reduce smoking for smokers not wanting to immediately quit helps reduce smoking and increase abstinence and physical activity, and to determine if this intervention is cost-effective.
Design
This was a multicentred, two-arm, parallel-group, randomised (1 : 1) controlled superiority trial with accompanying trial-based and model-based economic evaluations, and a process evaluation.
Setting and participants
Participants from health and other community settings in four English cities received either the intervention (
Intervention
The intervention consisted of up to eight face-to-face or telephone behavioural support sessions to reduce smoking and increase physical activity.
Main outcome measures
The main outcome measures were carbon monoxide-verified 6- and 12-month floating prolonged abstinence (primary outcome), self-reported number of cigarettes smoked per day, number of quit attempts and carbon monoxide-verified abstinence at 3 and 9 months. Furthermore, self-reported (3 and 9 months) and accelerometer-recorded (3 months) physical activity data were gathered. Process items, intervention costs and cost-effectiveness were also assessed.
Results
The average age of the sample was 49.8 years, and participants were predominantly from areas with socioeconomic deprivation and were moderately heavy smokers. The intervention was delivered with good fidelity. Few participants achieved carbon monoxide-verified 6-month prolonged abstinence [nine (2.0%) in the intervention group and four (0.9%) in the control group; adjusted odds ratio 2.30 (95% confidence interval 0.70 to 7.56)] or 12-month prolonged abstinence [six (1.3%) in the intervention group and one (0.2%) in the control group; adjusted odds ratio 6.33 (95% confidence interval 0.76 to 53.10)]. At 3 months, the intervention participants smoked fewer cigarettes than the control participants (21.1 vs. 26.8 per day). Intervention participants were more likely to reduce cigarettes by ≥ 50% by 3 months [18.9% vs. 10.5%; adjusted odds ratio 1.98 (95% confidence interval 1.35 to 2.90] and 9 months [14.4% vs. 10.0%; adjusted odds ratio 1.52 (95% confidence interval 1.01 to 2.29)], and reported more moderate-to-vigorous physical activity at 3 months [adjusted weekly mean difference of 81.61 minutes (95% confidence interval 28.75 to 134.47 minutes)], but not at 9 months. Increased physical activity did not mediate intervention effects on smoking. The intervention positively influenced most smoking and physical activity beliefs, with some intervention effects mediating changes in smoking and physical activity outcomes. The average intervention cost was estimated to be £239.18 per person, with an overall additional cost of £173.50 (95% confidence interval -£353.82 to £513.77) when considering intervention and health-care costs. The 1.1% absolute between-group difference in carbon monoxide-verified 6-month prolonged abstinence provided a small gain in lifetime quality-adjusted life-years (0.006), and a minimal saving in lifetime health-care costs (net saving £236).
Conclusions
There was no evidence that behavioural support for smoking reduction and increased physical activity led to meaningful increases in prolonged abstinence among smokers with no immediate plans to quit smoking. The intervention is not cost-effective.
Limitations
Prolonged abstinence rates were much lower than expected, meaning that the trial was underpowered to provide confidence that the intervention doubled prolonged abstinence.
Future work
Further research should explore the effects of the present intervention to support smokers who want to reduce prior to quitting, and/or extend the support available for prolonged reduction and abstinence.
Trial registration
This trial is registered as ISRCTN47776579.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in
NHS pharmacological and behavioural support helps smokers wanting to quit, and physical activity may also help. It is unclear if behavioural support for those not ready to quit may lead to more quit attempts and abstinence from smoking. A total of 915 smokers who wanted to reduce their smoking, but who had not yet quit, were recruited and randomised to receive an intervention or brief support as usual (brief advice to quit), in Plymouth, London, Oxford and Nottingham. The intervention involved up to eight sessions (by telephone or in person) of motivational support to reduce smoking and increase physical activity (and more sessions to support a quit attempt). Participants self-reported smoking and physical activity information at the start of the trial and after 3 and 9 months. Self-reported quitters confirmed their abstinence with a biochemical test of expired air or saliva. Our main interest was in whether or not the groups differed in the proportion who remained abstinent for at least 6 months. Overall, only 1–2% remained abstinent for 6 months. Although it appeared that a greater proportion did so after receiving the intervention, because few participants were abstinent, the results are not conclusive. However, the intervention had beneficial effects on less rigorous outcomes, including a reduction in the self-reported number of cigarettes smoked, and a greater proportion of intervention than control participants with self-reported and biochemically verified abstinence at 3 months. The intervention also helped participants to reduce, by at least half, the number of cigarettes they smoked at 3 and 9 months, and to report more physical activity, but only at 3 months. Despite reasonable intervention engagement and some short-term changes in smoking and physical activity, the trial does not provide evidence that this intervention would help smokers to quit for at least 6 months nor would it be cost-effective, with an average cost of £239 per smoker.
Autres résumés
Type: plain-language-summary
(eng)
NHS pharmacological and behavioural support helps smokers wanting to quit, and physical activity may also help. It is unclear if behavioural support for those not ready to quit may lead to more quit attempts and abstinence from smoking. A total of 915 smokers who wanted to reduce their smoking, but who had not yet quit, were recruited and randomised to receive an intervention or brief support as usual (brief advice to quit), in Plymouth, London, Oxford and Nottingham. The intervention involved up to eight sessions (by telephone or in person) of motivational support to reduce smoking and increase physical activity (and more sessions to support a quit attempt). Participants self-reported smoking and physical activity information at the start of the trial and after 3 and 9 months. Self-reported quitters confirmed their abstinence with a biochemical test of expired air or saliva. Our main interest was in whether or not the groups differed in the proportion who remained abstinent for at least 6 months. Overall, only 1–2% remained abstinent for 6 months. Although it appeared that a greater proportion did so after receiving the intervention, because few participants were abstinent, the results are not conclusive. However, the intervention had beneficial effects on less rigorous outcomes, including a reduction in the self-reported number of cigarettes smoked, and a greater proportion of intervention than control participants with self-reported and biochemically verified abstinence at 3 months. The intervention also helped participants to reduce, by at least half, the number of cigarettes they smoked at 3 and 9 months, and to report more physical activity, but only at 3 months. Despite reasonable intervention engagement and some short-term changes in smoking and physical activity, the trial does not provide evidence that this intervention would help smokers to quit for at least 6 months nor would it be cost-effective, with an average cost of £239 per smoker.
Identifiants
pubmed: 37022933
doi: 10.3310/KLTG1447
pmc: PMC10150295
doi:
Substances chimiques
Carbon Monoxide
7U1EE4V452
Banques de données
ISRCTN
['ISRCTN47776579']
Types de publication
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-277Subventions
Organisme : Department of Health
Pays : United Kingdom
Références
PLoS One. 2013 Aug 07;8(8):e71379
pubmed: 23940744
BMJ Open. 2020 Dec 1;10(12):e043331
pubmed: 33262194
BMJ Open. 2020 Jan 9;10(1):e029596
pubmed: 31924631
Addict Behav. 2011 Jul;36(7):764-8
pubmed: 21420791
J Consult Clin Psychol. 1997 Jun;65(3):448-52
pubmed: 9170768
Eur J Health Econ. 2013 Oct;14(5):789-97
pubmed: 22961230
Nicotine Tob Res. 2019 Apr 17;21(5):648-654
pubmed: 29579250
Addiction. 2008 Sep;103(9):1553-61
pubmed: 18783507
Int J Chron Obstruct Pulmon Dis. 2009;4:137-48
pubmed: 19436692
Am J Gastroenterol. 2015 Mar;110(3):368-77
pubmed: 25350768
Scand J Public Health. 2013 Feb;41(1):4-10
pubmed: 23160318
Health Technol Assess. 1998;2(16):iii-ix, 1-274
pubmed: 9919458
BMJ Open. 2017 Jul 20;7(7):e016375
pubmed: 28729321
Health Technol Assess. 2002;6(16):1-245
pubmed: 12269277
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
Med Care. 2009 Jan;47(1):115-20
pubmed: 19106739
JAMA. 1996 Apr 24;275(16):1247-51
pubmed: 8601956
Nicotine Tob Res. 2013 Sep;15(9):1519-27
pubmed: 23404735
Eur J Prev Cardiol. 2012 Oct;19(5):1173-83
pubmed: 21840967
Ann Behav Med. 2009 Jun;37(3):315-24
pubmed: 19373517
Addiction. 2005 Mar;100(3):299-303
pubmed: 15733243
Stat Methods Med Res. 1998 Jun;7(2):187-203
pubmed: 9654641
Hosp Pract (1995). 2012 Feb;40(1):24-34
pubmed: 22406880
Nicotine Tob Res. 2016 Jan;18(1):88-92
pubmed: 25744970
BMJ. 2010 Mar 23;340:c332
pubmed: 20332509
Addiction. 2005 Aug;100(8):1074-89
pubmed: 16042638
Tob Control. 2014 Sep;23(5):437-42
pubmed: 23748188
Ann Fam Med. 2017 Jan;15(1):37-47
pubmed: 28376459
CADTH Technol Overv. 2012;2(3):e2303
pubmed: 23002381
Health Rep. 2013 Feb;24(2):12-22
pubmed: 24257906
Int J Clin Pract. 2014 May;68(5):639-46
pubmed: 24472120
J Subst Abuse Treat. 2005 Jan;28(1):19-26
pubmed: 15723728
BMJ. 2004 Jun 26;328(7455):1519
pubmed: 15213107
Pharmacoeconomics. 2012 Sep 1;30(9):825-40
pubmed: 22799876
Am J Prev Med. 2016 May;50(5):573-583
pubmed: 26711164
Eur J Health Econ. 2018 Dec;19(9):1319-1333
pubmed: 29687268
Prev Med Rep. 2015 Mar 14;2:189-95
pubmed: 26844072
Sci Rep. 2016 Sep 01;6:31893
pubmed: 27583987
Addiction. 2013 Jan;108(1):26-37
pubmed: 22861822
Soc Sci Med. 1991;32(10):1151-9
pubmed: 2068598
Int J Epidemiol. 1998 Feb;27(1):27-32
pubmed: 9563690
Aten Primaria. 2017 Aug - Sep;49(7):407-416
pubmed: 28173951
Pharmacoeconomics. 2008;26(6):497-511
pubmed: 18489200
Tob Control. 2015 Sep;24(5):489-96
pubmed: 24935442
Am J Clin Nutr. 2017 Jun;105(6):1259-1271
pubmed: 28446497
Appl Health Econ Health Policy. 2016 Feb;14(1):77-87
pubmed: 26597111
Health Technol Assess. 2012;16(38):1-205, iii-v
pubmed: 23046909
J Clin Psychiatry. 2015 Oct;76(10):e1285-91
pubmed: 26528651
Prev Med. 2007 Apr;44(4):290-5
pubmed: 17222450
Ann Intern Med. 2005 Feb 15;142(4):233-9
pubmed: 15710956
Addiction. 2017 Jan;112(1):146-155
pubmed: 27566993
Nicotine Tob Res. 2009 May;11(5):475-80
pubmed: 19346506
Am J Public Health. 2002 Jun;92(6):990-6
pubmed: 12036794
Stat Med. 2012 Feb 20;31(4):328-40
pubmed: 22139891
Addiction. 2012 Mar;107(3):658-70
pubmed: 21883602
Am J Prev Med. 2010 Mar;38(3 Suppl):S364-72
pubmed: 20176309
Cochrane Database Syst Rev. 2019 Sep 30;9:CD013183
pubmed: 31565800
BMC Public Health. 2009 Jun 18;9:194
pubmed: 19538719
Nicotine Tob Res. 2014 Mar;16(3):270-8
pubmed: 24084467
Med Sci Sports Exerc. 2011 Jun;43(6):1085-93
pubmed: 21088628
BMJ. 2012 Jul 10;345:e4439
pubmed: 22782848
Psychopharmacology (Berl). 2014 Apr;231(7):1267-75
pubmed: 24522330
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Nicotine Tob Res. 2010 Dec;12(12):1228-35
pubmed: 21036960
Tob Control. 2009 Aug;18(4):262-7
pubmed: 19509003
Eur J Cardiovasc Prev Rehabil. 2008 Dec;15(6):663-9
pubmed: 18779737
J Health Econ. 1999 Jun;18(3):341-64
pubmed: 10537899
Addiction. 2014 Feb;109(2):314-22
pubmed: 24329972
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Ont Health Technol Assess Ser. 2012;12(12):1-61
pubmed: 23074422
Nicotine Tob Res. 2012 Apr;14(4):463-71
pubmed: 22232061
Health Technol Assess. 2018 Aug;22(41):1-84
pubmed: 30079863
Eur J Public Health. 2012 Dec;22(6):848-53
pubmed: 22241758
Int J Cancer. 2012 Sep 1;131(5):1210-9
pubmed: 22052329
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
J Consult Clin Psychol. 2004 Jun;72(3):371-81
pubmed: 15279521
Nicotine Tob Res. 2010 Jul;12(7):756-62
pubmed: 20504946
Nicotine Tob Res. 2016 Mar;18(3):267-74
pubmed: 25943761
J Public Health Med. 1997 Sep;19(3):268-73
pubmed: 9347449
COPD. 2009 Oct;6(5):369-79
pubmed: 19863366
BMC Med Res Methodol. 2019 Jan 21;19(1):19
pubmed: 30665353
N Engl J Med. 2008 Mar 13;358(11):1137-47
pubmed: 18272886
BMJ. 2010 Mar 23;340:c869
pubmed: 20332511
BMJ. 1994 Oct 8;309(6959):901-11
pubmed: 7755693
Health Econ. 2005 May;14(5):487-96
pubmed: 15497198
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006219
pubmed: 19160269
BMJ. 2000 Aug 5;321(7257):323-9
pubmed: 10926586
Lancet. 2016 Oct 8;388(10053):1659-1724
pubmed: 27733284
PLoS One. 2016 Feb 24;11(2):e0148750
pubmed: 26909802
BMJ. 2019 May 22;365:l1778
pubmed: 31122927
Health Psychol. 2018 Jul;37(7):627-637
pubmed: 29708387
Tob Control. 2015 Sep;24(5):481-8
pubmed: 24920575
Clinicoecon Outcomes Res. 2018 Jan 19;10:67-74
pubmed: 29403297
Health Psychol. 2014 Apr;33(4):349-359
pubmed: 23668849
Hosp Pract (1995). 2012 Feb;40(1):35-43
pubmed: 22406881
Math Popul Stud. 1998;7(1):29-49, 109
pubmed: 12321476
Am J Prev Med. 2010 Feb;38(2):138-44
pubmed: 20117569
BMC Public Health. 2017 Oct 2;17(1):765
pubmed: 28969669
Obes Rev. 2004 May;5(2):95-103
pubmed: 15086863
Clin Ther. 2012 Aug;34(8):1803-14
pubmed: 22818870
J Med Econ. 2017 Mar;20(3):246-252
pubmed: 27754739
Nicotine Tob Res. 2017 Aug 01;19(8):916-921
pubmed: 28182218
Addict Behav. 2015 Jun;45:79-86
pubmed: 25644592
Health Technol Assess. 2017 Jan;21(3):1-206
pubmed: 28121288
Cochrane Database Syst Rev. 2019 Oct 30;2019(10):
pubmed: 31684691
Popul Health Metr. 2003 Apr 14;1(1):4
pubmed: 12773212
BMJ. 2019 Sep 30;366:l5275
pubmed: 31570493
Addiction. 2016 Feb;111(2):340-50
pubmed: 26360507
Addiction. 2018 Apr;113(4):708-718
pubmed: 29105871
Tob Induc Dis. 2017 Mar 29;15:21
pubmed: 28360828
Nicotine Tob Res. 2002 Feb;4(1):95-100
pubmed: 11906685
Popul Dev Rev. 2005 Jun;31(2):259-292
pubmed: 25035524
Health Technol Assess. 2014 May;18(33):1-120
pubmed: 24831822
JAMA. 2000 Aug 9;284(6):706-12
pubmed: 10927778
Addiction. 2016 Feb;111(2):360-70
pubmed: 26370095
Scand J Med Sci Sports. 2017 Dec;27(12):1881-1892
pubmed: 27905148
J Appl Physiol (1985). 2014 Oct 1;117(7):738-44
pubmed: 25103964
N Engl J Med. 1991 Jun 6;324(23):1619-25
pubmed: 2030718
Prev Med. 2004 Dec;39(6):1156-63
pubmed: 15539050
Med Decis Making. 2009 Jul-Aug;29(4):500-2
pubmed: 19571330
Thorax. 2006 Nov;61(11):935-9
pubmed: 17071833
Cost Eff Resour Alloc. 2008 Jan 11;6:1
pubmed: 18190684
BMC Cancer. 2018 Dec 19;18(1):1275
pubmed: 30567516
Psychol Methods. 2002 Mar;7(1):83-104
pubmed: 11928892
Acta Clin Belg. 2012 Nov-Dec;67(6):416-22
pubmed: 23340147
Lancet. 1992 May 23;339(8804):1268-78
pubmed: 1349675
Br J Addict. 1989 Jul;84(7):791-9
pubmed: 2758152
N Engl J Med. 2013 Jan 24;368(4):341-50
pubmed: 23343063
N Engl J Med. 2006 Jan 26;354(4):333-42
pubmed: 16436765
Lancet Oncol. 2008 Jul;9(7):649-56
pubmed: 18556244
Med Sci Sports Exerc. 2014 Sep;46(9):1816-24
pubmed: 24887173
BMC Health Serv Res. 2010 Nov 25;10:317
pubmed: 21108797
Am J Epidemiol. 1985 Nov;122(5):794-804
pubmed: 3876763
Nicotine Tob Res. 2020 May 26;22(6):867-871
pubmed: 30868166
BMC Public Health. 2012 Mar 19;12:203
pubmed: 22429454
Pharmacoeconomics. 2018 Sep;36(9):1101-1112
pubmed: 29736894
Addiction. 2018 Jan;113(1):125-136
pubmed: 28734126
Health Technol Assess. 2014 Jan;18(4):1-324
pubmed: 24433837
BMC Health Serv Res. 2018 Mar 15;18(1):182
pubmed: 29544477
Tob Control. 2006 Aug;15(4):280-5
pubmed: 16885576
J Epidemiol. 2005 Sep;15(5):173-9
pubmed: 16195637
Health Psychol. 2004 Sep;23(5):443-51
pubmed: 15367063
Health Psychol. 2008 Nov;27(6):780-8
pubmed: 19025274
Nicotine Tob Res. 2016 Mar;18(3):289-97
pubmed: 25969453
Tob Control. 2014 May;23(3):223-30
pubmed: 23197369
Int J Technol Assess Health Care. 2009 Oct;25(4):522-9
pubmed: 19845982
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889
Cochrane Database Syst Rev. 2016 Oct 13;10:CD005231
pubmed: 27734465
Int J Tuberc Lung Dis. 2015 Jul;19(7):857-63
pubmed: 26056114